

The Importance of Early Diagnosis and Intervention in Chronic Kidney Disease: Calls-to-Action from Nephrologists Based Mainly in Central/Eastern Europe

Adrian Covic^a Marcus Säemann^{b,c} Jean Filipov^d Ryszard Gellert^e
Niels Gobin^f Bojan Jelaković^g Kairat Kabulbayev^h Merike Lumanⁱ
Marius Miglinas^{j,k} Ofri Mosenzon^{l,m} Adrián Okšaⁿ Milan Radovic^{o,p}
Benaya Rozen-Zvi^{q,r} Ieva Ziediņa^{s,t} Vladimír Tesar^u

^aDepartment of Nephrology, Grigore T. Popa University of Medicine, Iasi, Romania; ^b6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, Vienna, Austria; ^cMedical Faculty, Sigmund Freud University, Vienna, Austria; ^dDepartment of Nephrology and Transplantation, University Hospital “Alexandrovska”, Sofia, Bulgaria; ^eClinic of Nephrology and Internal Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland; ^fDepartment of Internal Medicine, Centre Hospitalier du Valais Romand, Sion, Switzerland; ^gDepartment for Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia; ^hDepartment of Nephrology, Kazakh National Medical University, Almaty, Kazakhstan; ⁱCentre of Nephrology, North Estonia Medical Centre, Tallinn, Estonia; ^jNephrology and Kidney Transplantation Unit, Nephrology Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; ^kFaculty of Medicine, Vilnius University, Vilnius, Lithuania; ^lDiabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; ^mRegeneron Pharmaceuticals, Tarrytown, NY, USA; ⁿDepartment of Clinical and Experimental Pharmacology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia; ^oClinic of Nephrology, University Clinical Centre of Serbia, Belgrade, Serbia; ^pFaculty of Medicine, University of Belgrade, Belgrade, Serbia; ^qNephrology and Hypertension Unit, Rabin Medical Center, Petah Tikva, Israel; ^rSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ^sRiga Stradins University, Riga, Latvia; ^tPauls Stradins Clinical University Hospital, Riga, Latvia; ^uDepartment of Nephrology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic

Keywords

Chronic kidney disease · Central Europe · Eastern Europe · Primary care · Call-to-action

Abstract

Background: Chronic kidney disease (CKD) has a global prevalence of 9.1–13.4%. Comorbidities are abundant and may cause and affect CKD. Cardiovascular disease strongly correlates with CKD, increasing the burden of both diseases. **Summary:** As a group of 15 clinical nephrologists primarily practicing in 12 Central/Eastern European countries, as well as Israel and Kazakhstan, herein we review the significant

unmet needs for patients with CKD and recommend several key calls-to-action. Early diagnosis and treatment are imperative to ensure optimal outcomes for patients with CKD, with the potential to greatly reduce both morbidity and mortality. Lack of awareness of CKD, substandard indicators of kidney function, suboptimal screening rates, and geographical disparities in reimbursement often hamper access to effective care. **Key Messages:** Our key calls-to-action to address these unmet needs, thus improving the standard of care for patients with CKD, are the following: increase disease awareness, such as through education; encourage provision of financial support for patients; develop screening algorithms; revisit primary care physician referral practices; and create epidemiological databases that rectify the paucity of data on early-stage disease. By focusing attention on early detection, diagnosis, and treatment of high-risk and early-stage CKD populations, we aim to reduce the burdens, progression, and mortality of CKD.

© 2024 The Author(s).
Published by S. Karger AG, Basel

Introduction

Chronic kidney disease (CKD) has a global prevalence of 9.1–13.4% [1–5]. In 2017, the Global Burden of Disease study found ~100 million Europeans were affected by CKD [1, 6]. CKD is the tenth most common cause of global mortality [7], projected to rise to fifth by 2040 [6, 8] and designating it a significant worldwide public health problem. The patient and societal burdens of CKD are increasing owing to ageing populations, growing medical costs, and associations between CKD and other diseases that are also increasing in prevalence [1–4, 6, 9–12].

The early stages of CKD tend to be asymptomatic, hampering timely diagnosis and treatment [13]. The management of CKD varies substantially across Europe [4, 12, 14], despite timely treatment being imperative to slow or even halt CKD progression and substantially reduce cardiovascular morbidity and mortality [1, 14]. Epidemiology also varies, with prevalence higher in Central and Eastern Europe (13.3%) than in Western Europe (10.1%) [1, 6]. Potential factors contributing to geographical variations in prevalence and management of CKD may include differences in awareness (particularly of early-stage disease, detection, screening policies, diagnosis, and early intervention); access to healthcare; use of potentially nephrotoxic drugs including non-steroidal anti-inflammatory drugs (NSAIDs); reimbursement policies for diagnosis and treatments; and patient demographics, e.g., nutrition, smoking, socioeconomics,

and physical activity [4, 12, 15, 16]. These factors culminate in underuse or misuse of treatment [1]; thus, a priority action is to improve primary care management of CKD in order to reduce disease progression, morbidity, and mortality [9, 17]. Guidelines issued by organisations such as Kidney Disease: Improving Global Outcomes (KDIGO) and the American Diabetes Association (ADA) recognise the importance of early CKD diagnosis and treatment, via screening high-risk populations. Such evidence-based guidelines further bolster the need for a systematic and multidisciplinary approach across Europe to hasten and improve care for patients with CKD.

We are a group of 15 clinical nephrologists based in 14 countries: seven in Central Europe (Austria, Croatia, Czech Republic, Poland, Republic of Serbia, Slovakia, Switzerland), three in Eastern Europe (Estonia, Latvia, Lithuania), and two in Southeast Europe (Bulgaria, Romania), in addition to one each in Asia/Eastern Europe (Kazakhstan) and the Middle East (Israel). Our 14 countries encompass a wide spectrum of economic development, reimbursement legislation, and healthcare systems. Herein we initially highlight the most significant unmet needs within CKD care, highlighting disease burden and the urgent need for early diagnosis and treatment. We subsequently provide a comprehensive overview of CKD diagnosis and treatment practices/policies in our respective countries. Finally, we recommend specific calls-to-action for the medical communities in our countries, including policymakers and clinicians (primary physicians, internists, cardiologists, diabetologists, endocrinologists, paediatricians, etc.), to raise awareness of CKD's burden and to improve its management. These calls-to-action are also of relevance beyond the 14 countries included in this article.

Disease Burden

CKD is strongly associated with a range of comorbidities [5], particularly cardiovascular disease (CVD), arterial hypertension, diabetes mellitus, and obesity [1, 2, 6, 12, 18], which are risk factors for both CKD onset and progression. CKD is a notable risk factor for CVD and CVD mortality [1]. A systematic analysis found that, in 2017 globally, 7.6% of CVD deaths resulted from impaired kidney function [1]. Patients with KDIGO CKD stage G3–4 are more likely to die from CVD than to progress to end-stage kidney disease [19]. The risk factors for CVD in CKD include hypertension, dyslipidaemia, hyperglycaemia, and vascular calcification [18]. Heart failure, especially with preserved ejection fraction, has

been recognised as a major complication of CKD; 40% of patients with chronic heart failure are estimated to have CKD [20] and CVD is the leading cause of death among CKD patients [21]. Accordingly, the 2021 European Society of Cardiology includes albuminuria as an independent risk factor for CVD [22]. The correlation between CKD and CVD ultimately increases disease burden; in 2017, 41.6% of disability-adjusted life years for patients with CVD were attributable to impaired kidney function [1].

The patient burden of CKD is higher for certain subgroups. For example, lower socioeconomic status, indicated by income and education, was significantly associated with CKD prevalence [23] and correlated with greater negative impact on patients' quality of life. The proportions of predialysis CKD patients with depression (47.1%) and anxiety (27.6%) are far greater than among the general population (where prevalence ranges from 2 to 21% [24] and 4–25%, respectively). Disease burden is also higher for older populations as ageing is associated with CKD [5]; as Central and Eastern European societies are ageing, partly due to economically motivated emigration to Western Europe, this contributes to CKD's increasing impact.

CKD and its associated comorbidities also lead to substantial healthcare resource utilisation, burdening both systems and patients. The likelihood of hospitalisation may be greater for patients with CKD than for those with non-metastatic cancer (adjusted relative rate, 1.55, 95% CI, 1.52–1.58) [25]. Another study found that hospital stays are longer, and thus more costly, for patients with non-communicable diseases when occurring in conjunction with CKD than without CKD [26].

Importance of Early Diagnosis and Treatment

Current treatment tools for CKD include renin-angiotensin-system inhibitors, statins, antiplatelet therapy, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and non-steroidal mineralocorticoid receptor antagonists [27, 28]. For patients at high risk of CKD development and progression (i.e., those with CVD, diabetes, obesity, HIV infection, multisystem disease with potential kidney involvement, family history of kidney disease, age >60 years), guidelines typically recommend regular screening to enable timely intervention, halting or delaying CKD progression [29]. Patients with estimated glomerular filtration rate (eGFR) categories G4–G5 (<30 mL/min/1.73 m²), albuminuria (albumin-to-creatinine ratio [ACR] ≥300 mg/mmol), or substantial

eGFR decline should be consulted by a nephrologist as soon as possible [30].

Arterial hypertension is a leading cause of worsening kidney function and progression to end-stage kidney disease; thus, adequate control of hypertension in patients with CKD is important, especially due to the bidirectional relationship between these two conditions. Lowering blood pressure via pharmacological and lifestyle interventions can reduce eGFR decline, disease progression, and incidence of CVD in people with CKD [19]. Hence, blood pressure regulation is a key strategy for limiting kidney damage and reducing morbidity and mortality in patients with hypertension [31]. Early treatment of CKD and comorbid cardiovascular risk factors and diseases using SGLT2 inhibitors has also been hypothesised to prevent cognitive impairment [32].

Primary care physicians have a crucial role in CKD risk stratification and accurate diagnosis (e.g., acute kidney injury vs. CKD), ideally before consulting with a nephrologist [27, 33]. The initial stages tend to be asymptomatic; fewer than 5% of patients are aware that they have early-stage CKD [27], highlighting the importance of (a) earlier screening and (b) focusing on high-risk patients in primary care to detect CKD. Furthermore, screening for early-stage CKD is pivotal to reduce morbidity and mortality [17, 27, 30], enabling the medical community to act more effectively in preventing CKD progression and its deleterious sequelae [30]. KDIGO guidelines, endorsed by the ADA, recommend that the frequency of screening/monitoring should correspond to the likelihood of disease progression (patients with the most severely decreased GFR and increased albuminuria should be monitored most regularly) [17, 34]. CKD stage G3a is considered a turning point in disease progression and emphasises the importance of early and correct staging [30].

While international guidelines (e.g., KDIGO) provide excellent general recommendations for screening/monitoring and treatment, local/national guidelines should also be consulted [30, 35]. Local guidelines do vary. For example, nephrologists and diabetologists in Slovakia have developed guidelines (last updated 2021) stating that a diabetic patient with eGFR <60 mL/min/1.73 m² and/or albuminuria >300 mg/day (or proteinuria >0.5 g/day) should be consulted by a nephrologist [36]. On the other hand, Bulgarian guidelines recommend nephrologist referral at eGFR <30 mL/min/1.73 m², with earlier referral in cases of suspected non-diabetic glomerular disease or rapid decline in kidney function [37].




Fig. 1. Map of reimbursement policies for CKD by diagnosis/evaluation and treatment. AT, Austria; BG, Bulgaria; CR, Croatia; CZ, Czech Republic; E, Estonia; IL, Israel; KZ, Kazakhstan; LV, Latvia; LT, Lithuania; PL, Poland; RO, Romania; RS, Republic of Serbia; SK, Slovakia; SW, Switzerland.

Barriers to Diagnosis and Treatment

Patients with CKD experience significant barriers to diagnosis and treatment. Although major clinical practice guidelines identify eGFR as the preferred indicator of kidney function, serum creatinine continues to be the most widely used endogenous marker [38]. Additionally, screening via ACR measurement is widely recommended for individuals at high risk of CKD [39–41]; however, suboptimal ACR screening rates result in many undiagnosed CKD cases, particularly at early stages (G1–2) [42]. Despite recognition that screening for early CKD in high-risk groups is cost-effective, financial incentives, such as pay-for-performance programmes, are lacking [17]. Other reasons for the suboptimal screening rate include low awareness of CKD amongst healthcare professionals (HCPs), the perceived complex nature of CKD, and a lack of standardised and structured CKD care outside of that given in nephrology departments. Such barriers to early CKD diagnosis and management may impede timely and efficient treatment.

Restrictive reimbursement policies are a significant financial barrier to CKD treatment. Only a small proportion of countries worldwide provide free or subsidised treatment for CKD patients. According to the Global Kidney Health Atlas, only 28% (45/159) of countries provide free treatment and only 20% (32/159) offer subsidies [4].

Figures 1 and 2 and online supplementary Table 1 (for all online suppl. material, see <https://doi.org/10.1159/000538765>) summarise the reimbursement policies for CKD diagnosis/evaluation and treatment in the 14 countries in which we practice as clinical nephrologists: seven in Central Europe (Austria, Croatia, Czech Republic, Poland, Republic of Serbia, Slovakia, Switzerland), three in Eastern Europe (Estonia, Latvia, Lithuania), and two in Southeast Europe (Bulgaria, Romania), in addition to one each in Asia/Eastern Europe (Kazakhstan) and the Middle East (Israel). Reimbursement for diagnosis and evaluation of CKD varies by country across our 14 nations and, as shown on the map of Europe (Fig. 1), is generally less comprehensive in the east. As shown in detail in online supplementary Table 1, country-specific limitations may be placed upon screening reimbursement, such as to particular patients and healthcare settings in Bulgaria and Romania. In Bulgaria, albuminuria testing is only reimbursed for people with diabetes or if ordered by a nephrologist, the latter being notable because patients with undiagnosed early-stage CKD may present first to primary care practitioners, thus delaying treatment. In Romania, ACR reimbursement may also be limited to secondary and tertiary healthcare services. Other country-specific issues regarding diagnosis/evaluation and treatment of CKD are covered in detail in online supplementary Table 1.

		Austria	Bulgaria	Croatia	Czech Republic	Poland	Republic of Serbia	Romania	Slovakia	Switzerland	Estonia	Latvia	Lithuania	Israel	Republic of Kazakhstan	
Diagnosis and evaluation	Screening measures*	Orange	Orange	Green	Green	Orange	Orange	Orange	Orange	Green	Green	Green	Green	Green	Orange	
	Imaging	Green	Orange	Green	Green	Green	Green	Green	Green	Green	Green	Orange	Green	Green	Green	
	Biopsy	Green	Orange	Green	Green	Green	Green	Green	Green	Green	Green	Orange	Green	Green	Green	
Treatment	ACE	Green	Orange	Green	Green	Orange	Green	Green	Green	Green	Orange	Red	Green	Green	Green	
	ARB	Green	Orange	Green	Green	Orange	Green	Green	Green	Green	Green	Red	Green	Green	Green	
	SGLT2 inhibitors†	Green	Orange	Orange	Orange	Orange	Red	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Red
	GLP-1 RA	Green	Green	Green	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Orange	Green
	Calcium-based phosphate binders	Green	Orange	Orange	Green	Orange	Green	Orange	Green	Green	Green	Orange	Green	Green	Orange	Orange
	Calcimimetics	Green	Orange	Green	Green	Orange	Green	Orange	Green	Orange	Green	Orange	Green	Orange	Orange	Orange
	Stains	Green	Orange	Green	Green	Orange	Green	Orange	Green	Green	Green	Orange	Green	Green	Orange	Green
	Diuretics	Green	Orange	Green	Green	Orange	Green	Orange	Green	Green	Green	Orange	Red	Green	Orange	Orange
	Medications for anaemia‡	Green	Green	Green	Green	Orange	Green	Green	Orange	Green	Green	Orange	Green	Green	Orange	Orange
	Supplements§	Green	Green	Green	Green	Orange	Green	Green	Orange	Green	Green	Orange	Green	Green	Orange	Orange

Fig. 2. Country-specific reimbursement policies for CKD by diagnosis and evaluation method and treatment. *Screening measures include ACR, eGFR, serum creatinine, blood chemistry. †SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin. ‡Medications for anaemia include ESA and iron preparations. §Vitamin D analogues include calcitriol and paricalcitol. Figure is based on authors' perspectives. Colour coding is as follows: green represents good levels of reimbursement, e.g., full reimbursement or numerous screening/

treatment options. Orange represents partial reimbursement policies, or full reimbursement with criteria and restrictions, e.g., full reimbursement dependent on the speciality of the prescribing HCP. Red represents no reimbursement. ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2, sodium-glucose co-transporter-2.

As expected, there is a complex picture of therapeutic reimbursement policies across our 14 nations (Fig. 1, 2; online suppl. Table 1). Across most of the 12 Central/Eastern European countries, SGLT2 inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and calcimimetics are only partially reimbursed and limitations are placed based on the speciality of the prescribing HCP. For instance, in Bulgaria, full SGLT2 inhibitor reimbursement is only applicable if prescribed by endocrinologists, with partial reimbursement when prescribed by other specialists, and in the Czech Republic SGLT2 inhibitors are fully financed when prescribed by a nephrologist. Other examples of reimbursement restrictions

include that SGLT2 inhibitors may only be reimbursed for patients with type 2 diabetes, such as in the Republic of Serbia, Latvia, Lithuania, and Kazakhstan. Some nations offer only partial reimbursement for treatments, as in Estonia, where the costs for angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), SGLT2 inhibitors, and GLP-1 RAs are 75% reimbursed for most patients. ACE inhibitors and ARBs are fully reimbursed across most of the countries. Furthermore, calcium-based phosphate binders, statins, diuretics, medications for anaemia (erythropoiesis-stimulating agents and iron preparations), and supplements (vitamin D analogues, including calcitriol and




Fig. 3. Calls-to-action for improving the management of CKD from expert perspectives. CKD, chronic kidney disease; eGFR, glomerular filtration rate.

paricalcitol) are typically fully reimbursed. It is noteworthy that Latvia reports particularly restrictive reimbursement policies, with ACE inhibitors, ARBs, and statins not eligible for any reimbursement. Thus, this review highlights that geographical disparities in the availability of financially accessible care are likely to hamper timely CKD diagnosis and treatment.

Demographic factors, such as race and age, can also lead to barriers to effective CKD diagnosis and treatment [43]. Black patients may be disproportionately underdiagnosed and undertreated because current equations, which incorporate race, might overestimate eGFR values [43, 44]. Renal function decreases with age, even in healthy individuals, not uncommonly to the level of the CKD definition, which means that the use of a fixed eGFR threshold to diagnose CKD in older patients could lead to overdiagnosis [44]. Therefore, if a specific threshold is to be used for detecting actual CKD in elderly people, it could be more accurate to have it specified as 45 mL/min/1.73 m², not as 60 mL/min/1.73 m² [45]. In the absence of additional symptoms, it has been recommended to primary care physicians not to refer elderly patients based on a reduction in eGFR alone, if simply exhibiting normal age-related kidney decline. We do, however, acknowledge the importance of considering referral in the instance of lower GFR to ensure that a renal pathology is not overlooked.

Calls-to-Action: Based on Expert Opinion

The overriding goals of CKD management are to prevent/delay renal disease progression and complications (especially CVD), thus potentially increasing life-span and quality of life. Here, we outline some calls-to-action to achieve these goals (Fig. 3).

Increase Awareness: Educate Clinicians and the Public

Nephrologists in Balkan countries recently warned of low societal awareness of CKD, which hinders early diagnosis and treatment [46]. In Central and Eastern Europe, the main route of disseminating information to the public is the coordinated campaign on World Kidney Day by representatives from medical societies. To promote knowledge of CKD among the public and clinicians, we recommend the following four approaches to be considered:

1. Community educators should lead discussions around CKD screening and appropriate diagnostic tests, to break down barriers such as taboo topics like urogenital symptoms and to support better physician-patient communication. To ensure a broad and comprehensive education programme, different renal topics should be raised at different times annually. Pharmacists should be included in future communication strategies,

particularly to aid patient awareness of renal risks associated with NSAIDs as part of a wider strategy to curb NSAID use.

2. Greater media presence of key opinion leaders and medical representatives would inform patients of their treatment options and, crucially, the importance of early intervention.
3. Development of strategic education programmes (setting out the gold standard of care) would increase knowledge sharing and communication among HCPs. Such programmes should be endorsed by as many medical societies as possible, such as those encompassing primary care, CKD, and medical practice more widely. Education opportunities, such as the annual European Kidney Forum hosted by the European Kidney Health Alliance and Members of the European Parliament (MEP) Group for Kidney Health, enable upskilling and networking with other HCPs and MEPs. However, this is aimed at nephrology practitioners and patient representatives, rather than across a broader range of specialities. Clinical comprehension of CKD and its risk factors is important among the whole medical community because a variety of specialities (including primary care clinicians, internists, cardiologists, and endocrinologists) often assess the patient and prescribe treatment before consultation with a nephrologist. This is particularly the case for specialists treating patients with common comorbidities (e.g., cardiologists). It is paramount that these specialists receive education on screening guidelines and predictors of patient survival (such as eGFR), in order to initiate nephroprotective measures as early as possible.
4. Establishment of a coordinated CKD management programme outside of the nephrology department would provide clearer guidance for the wider medical community, especially cardiologists and diabetologists, and may encourage HCPs to discuss issues regarding diagnostic and treatment strategies, disease awareness, and reimbursement.

Provide Financial Support: Public and/or Private Options

Despite its global burden, CKD is rarely included in major chronic disease control strategies, impeding governments from properly addressing CKD in national policy. While full financial support from public healthcare services may be unattainable, hybrid options could be actively sought, i.e., combining public funding and private insurance. The contribution of private insurance companies is hugely impactful [12], although the medical history exclusion criteria of many policies could lead to a predominant use by healthier people. We therefore recommend a multidisciplinary

panel of primary care physicians, internists, and nephrologists to advise governing health authorities and policymakers on how to improve CKD awareness, diagnose early, and inform management policies.

Screen High-Risk Patient Populations

Whilst early detection can avert CKD progression and complications, in some Central/Eastern European countries screening rates continue to be suboptimal. The Swiss Society of Nephrology has created a booklet for primary care physicians listing conditions with increased CKD risk that should warrant CKD screening, but strategies must be employed to ensure guidance translates to practice change both nationally and internationally. We recommend the following:

1. mandatory targeted screening in high-risk populations for stage G1 and G2 CKD by primary healthcare providers;
2. provision of up-to-date information on risk factors and effective screening procedures, developed by a multidisciplinary panel, promoted via educational materials and events (congresses, webinars, etc.);
3. implementation of a common EU policy for mandatory CKD screening to ensure that effective screening practices are upheld.

Timely Consultation: Including by Nephrologists

In Europe, consultation with primary healthcare services can be delayed, often leading to patients presenting to nephrologists with burdensome later-stage CKD. We recommend that national healthcare services take steps to ensure primary care providers are aware of when a referral to nephrology is appropriate and to encourage consultation or referral as soon as clinical thresholds are met, as well as for individuals with functional renal abnormalities (e.g., a rapid fall in GFR and/or a large increase in ACR). We recognise that consultation by a nephrologist for all patients with CKD stage G3a may overburden already stretched health services; thus, we recommend consultation with a nephrologist for those with eGFR <60 mL/min/1.73 m² and nephrology referral for eGFR <30 mL/min/1.73 m². Nephrology referral does not necessarily mean total takeover from primary care services, although patients with considerable GFR reductions may require specialist kidney care services.

Better practice may boost the attractiveness of the nephrology speciality, increase the availability of treatment, and may culminate in the development of a European nephrology “agenda.” We recommend this “agenda” as a platform to call for initiatives such as telemetric CKD data, expert centres, prevention of

unnecessary patient travel between hospitals and to generally raise awareness of CKD among medical specialists and the public. Cooperation between nephrologists and paediatricians is required to identify high-risk paediatric populations, such as young patients with diabetes or genetic forms of CKD, who are at increased risk of developing or progressing to advanced CKD as adults. For example, in Bulgaria, paediatric nephrologists participate in scientific activities in the nephrology community to provide expert knowledge on these high-risk groups.

Create Epidemiological Databases

Epidemiological databases are lacking in Europe, especially on the prevalence and incidence of early-stage CKD. We recommend the development of agreed measurements and standardised techniques to formulate a large, dynamic database including albuminuria and kidney function values, management strategies, and outcome measures. The first step could be implementation within a single city, unifying a database among hospital laboratories, with expansion nationwide and eventually internationally. In addition, we recommend that future registry designs and clinical studies should include all CKD stages, not just late stage, to generate the data necessary to establish a more comprehensive understanding of CKD. Retrospective data are imperative to improve prevention and treatment strategies, inform healthcare policies, and advise the geographical placement of nephrologists. In particular, real-world data may provide an accurate representation of the burden across a region and guide the medical community on where to focus disease management strategies [12]. In the future, combined use of computerised medical files and artificial intelligence may expedite the database process and how it informs the medical community.

Conclusions

CKD is a major public health issue, associated with a wide range of comorbidities and complex management requirements. Focusing professional and societal attention on timely detection and therapeutic intervention in high-risk, early-stage CKD populations is, in our view, the most efficient method to reduce disease burden and ultimately save lives. Here, we have outlined some important calls-to-action for the wider medical community, namely, primary care physicians, internists, cardiologists, diabetologists, and paediatricians, along with nephrologists. Recommendations include increasing disease

awareness publicly and among clinicians, such as through guidance to professional societies; developing epidemiological databases to advise health authorities and insurance policymakers; and implementing robust detection and consultation schemes centered on primary care physicians and their key role in timely CKD management.

Acknowledgments

Writing support was provided by Lauren Rainer, Morgan Steigmann, and Michael Riley of Fortis Pharma Consulting. All opinions are the authors' own. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

Conflict of Interest Statement

Adrian Covic received consultancy fees from Boehringer Ingelheim and FMC; received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca and Boehringer Ingelheim; participated on advisory boards for Astra Zeneca, Boehringer Ingelheim, and Strada; and has a leadership role within the Romanian Society Nephrology and the European Dialysis Working Group (part of the European Renal Association). Jean Filipov received honoraria for lectures, presentations, bureaus, manuscripts, or events from Berlin Chemie, Boehringer Ingelheim, and Swixx Biopharma and participated on advisory boards for Boehringer Ingelheim. Ryszard Gellert received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca, Astellas, Bayer, Boehringer Ingelheim, Fresenius Kabi, Fresenius Medical Care and had a leadership role in the Ministry of Health as National Consultant of Nephrology. Niels Gobin received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca, Boehringer Ingelheim, and Pierre Fabre and participated on advisory boards for Astra Zeneca and Boehringer Ingelheim. Bojan Jelaković received consulting fees and personal fees from Berlin Chemie, Boehringer Ingelheim, and Servier; received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Krka, Norvasc, Servier, and Viatris; and has other financial or non-financial interests within AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk, Servier, and Viatris. Kairat Kabulbayev received support for attending meetings and/or travel from Boehringer Ingelheim. Merike Luman received consulting fees from Astellas Pharma and Bayer; received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca, Bayer, Boehringer Ingelheim; participated in advisory boards with Astra Zeneca and Boehringer Ingelheim; and member of the board for the Estonian Society of Nephrology. Marius Miglinas received honoraria for lectures, presentations, or events from Astellas Pharma, Astra Zeneca, Baxter, Bayer, Berlin Chemie, Boehringer Ingelheim, KRKA, Servier, Medtronic, Norameda, Novo Nordisk, Swixx Biopharma, and Viatris; participated in advisory boards with Astellas, Astra Zeneca, and Boehringer Ingelheim; and is President of Lithuanian Hypertension Society and Chairman of

Lithuanian Kidney Foundation. Ofri Mosenzon received consulting fees from Astra Zeneca, Bayer, Boehringer Ingelheim, Lilly, and Novo Nordisk; received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca, Bayer, Boehringer Ingelheim, Lilly, and Novo Nordisk; received payment for expert testimony from Novo Nordisk; and is a full-time employee of Regeneron Pharmaceuticals. Adrián Okša received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astellas Pharma, Astra Zeneca, Bayer, Boehringer Ingelheim, and Mundi Pharma and participated in advisory boards with Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Mundi Pharma, and Novo Nordisk. Milan Radović supported by grant number 200110, Ministry of Education, Science and Technological Development, Republic of Serbia; has received honoraria for lectures, presentations, bureaus, manuscripts, or events from Amicus Therapeutics, Astra Zeneca, Baxter, Berlin Chemie, Boehringer Ingelheim, Fresenius Medical Care, and Swixx Biopharma; and participated on advisory boards for Amicus Therapeutics, Astra Zeneca, Boehringer Ingelheim, Pharm Olam, and Swixx Biopharma. Benaya Rozen-Zvi received consulting fees from Astra Zeneca, Bayer, Boehringer Ingelheim, Fresenius, and Novartis and received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca and Bayer. Marcus Säemann received consulting fees from Astra Zeneca, Baxter, Bayer, Boehringer-Ingelheim, Novartis, Otsuka, and Vifor; received honoraria for lectures, presentations, bureaus, manuscripts, or events from Astra Zeneca, Baxter, Bayer, Boehringer-Ingelheim, Novartis, Otsuka, and Vifor; and is President of the Austrian Society of Nephrology. Vladimir Tesar received consulting fees from Astra Zeneca and Boehringer Ingelheim and is a member of the executive council of International Society of Nephrology (2021–2023). Ieva Ziedina received consulting fees from Astellas Pharma and Bayer; received honoraria for lectures, presentations,

bureaus, manuscripts, or events from Astra Zeneca, Bayer, Boehringer Ingelheim, Norameda, and Swixx Biopharma; participated on advisory boards for Bayer; and is President of Latvian Association of Nephrology.

Funding Sources

This study was funded by Boehringer Ingelheim. The authors did not receive payment related to the development of the manuscript.

Author Contributions

Adrian Covic, Jean Filipov, Ryszard Gellert, Niels Gobin, Bojan Jelaković, Kairat Kabulbayev, Merike Luman, Marius Miglinas, Ofri Mosenzon, Adrián Okša, Milan Radović, Benaya Rozen-Zvi, Marcus Säemann, Vladimir Tesar, and Ieva Ziedina substantially contributed to the conception, acquisition, and interpretation of data for the manuscript; critically revised manuscript drafts for intellectual content; approval of final version to be published; and agreed to be accountable for all aspects, accuracy, and integrity of the manuscript.

Data Availability Statement

No new data were generated or analysed in support of this manuscript.

References

- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709–33. doi: [10.1016/S0140-6736\(20\)30045-3](https://doi.org/10.1016/S0140-6736(20)30045-3).
- Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl*. 2022; 12(1):7–11. doi: [10.1016/j.kisu.2021.11.003](https://doi.org/10.1016/j.kisu.2021.11.003).
- Sundstrom J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study. *Lancet Reg Health Eur*. 2022;20:100438. doi: [10.1016/j.lanepe.2022.100438](https://doi.org/10.1016/j.lanepe.2022.100438).
- Bello A, Levin A, Lunney M, Osman M, Ye F, Ashuntantang G, et al. Global Kidney Health Atlas: a report by the International Society of Nephrology on the global burden of end-stage kidney disease and capacity for kidney replacement therapy and conservative care across world countries and regions. Brussels, Belgium: International Society of Nephrology; 2019.
- Ponte B, Pruijm M, Marques-Vidal P, Martin PY, Burnier M, Paccaud F, et al. Determinants and burden of chronic kidney disease in the population-based CoLaus study: a cross-sectional analysis. *Nephrol Dial Transplant*. 2013;28(9):2329–39. doi: [10.1093/ndt/gft206](https://doi.org/10.1093/ndt/gft206).
- Vanholder R, Annemans L, Bello AK, Bikbov B, Gallego D, Gansevoort RT, et al. Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. *Clin Kidney J*. 2021;14(7):1719–30. doi: [10.1093/ckj/sfab070](https://doi.org/10.1093/ckj/sfab070).
- World Health Organization. Global health estimates 2019: deaths by cause, age, sex, by country and by region, 2000–2019; 2020.
- Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *Lancet*. 2018;392(10159):2052–90. doi: [10.1016/S0140-6736\(18\)31694-5](https://doi.org/10.1016/S0140-6736(18)31694-5).
- Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. *J Gen Intern Med*. 2011;26(4):379–85. doi: [10.1007/s11606-010-1511-x](https://doi.org/10.1007/s11606-010-1511-x).
- Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet*. 2012;380(9854):1662–73. doi: [10.1016/S0140-6736\(12\)61350-6](https://doi.org/10.1016/S0140-6736(12)61350-6).
- Yim HE, Yoo KH. Obesity and chronic kidney disease: prevalence, mechanism, and management. *Clin Exp Pediatr*. 2021;64(10):511–8. doi: [10.3345/cep.2021.00108](https://doi.org/10.3345/cep.2021.00108).
- Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, et al. CKD prevalence varies across the European general population. *J Am Soc Nephrol*. 2016;27(7):2135–47. doi: [10.1681/ASN.2015050542](https://doi.org/10.1681/ASN.2015050542).
- Senanayake S, Gunawardena N, Paliyawadana P, Senanayake S, Karunarathna R, Kumara P, et al. Health related quality of life in chronic kidney disease; a descriptive study in a rural Sri Lankan community affected by chronic kidney disease. *Health Qual Life Outcomes*. 2020; 18(1):106. doi: [10.1186/s12955-020-01369-1](https://doi.org/10.1186/s12955-020-01369-1).

- 14 Rutkowski B, Król E. Epidemiology of chronic kidney disease in Central and Eastern Europe. *Blood Purif*. 2008;26(4):381–5. doi: [10.1159/000137275](https://doi.org/10.1159/000137275).
- 15 Inotai A, Hanko B, Meszaros A. Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. *Pharmacoepidemiol Drug Saf*. 2010;19(2):183–90. doi: [10.1002/pds.1893](https://doi.org/10.1002/pds.1893).
- 16 Lucas GNC, Leitao ACC, Alencar RL, Xavier RMF, Daher EDF, Silva Junior GBD. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. *J Bras Nefrol*. 2019;41(1):124–30. doi: [10.1590/2175-8239-JBN-2018-0107](https://doi.org/10.1590/2175-8239-JBN-2018-0107).
- 17 Shlipak MG, Tummalaapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. *Kidney Int*. 2021;99(1):34–47. doi: [10.1016/j.kint.2020.10.012](https://doi.org/10.1016/j.kint.2020.10.012).
- 18 Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. *Circulation*. 2021;143(11):1157–72. doi: [10.1161/CIRCULATIONAHA.120.050686](https://doi.org/10.1161/CIRCULATIONAHA.120.050686).
- 19 Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. *Drugs*. 2019;79(4):365–79. doi: [10.1007/s40265-019-1064-1](https://doi.org/10.1007/s40265-019-1064-1).
- 20 Tuegel C, Bansal N. Heart failure in patients with kidney disease. *Heart*. 2017;103(23):1848–53. doi: [10.1136/heartjnl-2016-310794](https://doi.org/10.1136/heartjnl-2016-310794).
- 21 Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-specific deaths in non-dialysis-dependent CKD. *J Am Soc Nephrol*. 2015;26(10):2512–20. doi: [10.1681/ASN.2014101034](https://doi.org/10.1681/ASN.2014101034).
- 22 Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227–337. doi: [10.1093/eurheartj/ehab484](https://doi.org/10.1093/eurheartj/ehab484).
- 23 Zeng X, Liu J, Tao S, Hong HG, Li Y, Fu P. Associations between socioeconomic status and chronic kidney disease: a meta-analysis. *J Epidemiol Community Health*. 2018;72(4):270–9. doi: [10.1136/jech-2017-209815](https://doi.org/10.1136/jech-2017-209815).
- 24 Gutiérrez-Rojas L, Porrás-Segovia A, Dunne H, Andrade-González N, Cervilla JA. Prevalence and correlates of major depressive disorder: a systematic review. *Braz J Psychiatry*. 2020;42(6):657–72. doi: [10.1590/1516-4446-2020-0650](https://doi.org/10.1590/1516-4446-2020-0650).
- 25 Tonelli M, Lloyd A, Cheung WY, Hemmelgarn BR, James MT, Ravani P, et al. Mortality and resource use among individuals with chronic kidney disease or cancer in Alberta, Canada, 2004–2015. *JAMA Netw Open*. 2022;5(1):e2144713. doi: [10.1001/jamanetworkopen.2021.44713](https://doi.org/10.1001/jamanetworkopen.2021.44713).
- 26 Yang C, Long J, Shi Y, Zhou Z, Wang J, Zhao MH, et al. Healthcare resource utilisation for chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study. *BMJ Open*. 2022;12(1):e051888. doi: [10.1136/bmjopen-2021-051888](https://doi.org/10.1136/bmjopen-2021-051888).
- 27 Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. *JAMA*. 2019;322(13):1294–304. doi: [10.1001/jama.2019.14745](https://doi.org/10.1001/jama.2019.14745).
- 28 Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. *Ann Intern Med*. 2023;176(3):381–7. doi: [10.7326/M22-2904](https://doi.org/10.7326/M22-2904).
- 29 George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. *BMJ Glob Health*. 2017;2(2):e000256. doi: [10.1136/bmjgh-2016-000256](https://doi.org/10.1136/bmjgh-2016-000256).
- 30 Kidney Disease: Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease; 2013.
- 31 Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. *J Hum Hypertens*. 2014;28(2):74–9. doi: [10.1038/jhh.2013.55](https://doi.org/10.1038/jhh.2013.55).
- 32 Noel JA, Hougen I, Sood MM. The intersection of SGLT2 inhibitors, cognitive impairment, and CKD. *Front Neurol*. 2022;13:823569. doi: [10.3389/fneur.2022.823569](https://doi.org/10.3389/fneur.2022.823569).
- 33 Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. *Pragmat Obs Res*. 2016;7:21–32. doi: [10.2147/POR.S97310](https://doi.org/10.2147/POR.S97310).
- 34 de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*. 2022;45(12):3075–90. doi: [10.2337/dci22-0027](https://doi.org/10.2337/dci22-0027).
- 35 Kidney Disease Improving Global Outcomes ISoN. ISN-KDIGO Chronic Kidney Disease Early Identification and Intervention Toolkit. 2022.
- 36 Okša A, Schroner Z, Rašlová K, Martinka E, Uličiansky V. Diabetická nefropatia: chronická choroba obličiek pri diabetes mellitus: diagnostika, prevencia a liečba. *Diab Obez*. 2021;21:5–12.
- 37 Bulgarian Society of Endocrinology. Recommendations for good clinical practice in diabetes mellitus 2019. Ministry of Health; 2019.
- 38 Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory: a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2020;22(4):584–603. doi: [10.1002/ehf.1697](https://doi.org/10.1002/ehf.1697).
- 39 Professional Practice Committee. Professional Practice Committee: Standards of medical care in diabetes—2021. *Diabetes Care*. 2020;44(Supplement_1):S3–S.
- 40 de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go? *Clin J Am Soc Nephrol*. 2008;3(2):616–23. doi: [10.2215/CJN.04381007](https://doi.org/10.2215/CJN.04381007).
- 41 Chronic NICE. Kidney disease: assessment and management NICE guideline 2021.
- 42 Shin JI, Chang AR, Grams ME, Coresh J, Ballew SH, Surapaneni A, et al. Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium. *Hypertension*. 2021;78(4):1042–52. doi: [10.1161/HYPERTENSIONAHA.121.17323](https://doi.org/10.1161/HYPERTENSIONAHA.121.17323).
- 43 Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*. 2021;385(19):1737–49. doi: [10.1056/NEJMoa2102953](https://doi.org/10.1056/NEJMoa2102953).
- 44 Denic A, Glasscock RJ, Rule AD. Structural and functional changes with the aging kidney. *Adv Chronic Kidney Dis*. 2016;23(1):19–28. doi: [10.1053/j.ackd.2015.08.004](https://doi.org/10.1053/j.ackd.2015.08.004).
- 45 Liu P, Quinn RR, Lam NN, Elliott MJ, Xu Y, James MT, et al. Accounting for age in the definition of chronic kidney disease. *JAMA Intern Med*. 2021;181(10):1359–66. doi: [10.1001/jamainternmed.2021.4813](https://doi.org/10.1001/jamainternmed.2021.4813).
- 46 Mitić I, Laganović M, Marinova I, Gancheva N, Nakić V, Melentijević D, et al. Chronic kidney disease in Balkan countries: a call to action for timely diagnosis and monitoring. *Diagnostics*. 2022;12(9):2162. doi: [10.3390/diagnostics12092162](https://doi.org/10.3390/diagnostics12092162).